UNLOXCYT™ (cosibelimab-ipdl)
Cutaneous Squamous Cell Carcinoma (cSCC)
Approved/CommercialApproved (Royalty Asset)
Key Facts
Indication
Cutaneous Squamous Cell Carcinoma (cSCC)
Phase
Approved/Commercial
Status
Approved (Royalty Asset)
Company
About Fortress Biotech
Fortress Biotech operates as a biopharmaceutical accelerator, utilizing a flexible, therapeutic area-agnostic model to identify and advance high-potential assets. The company has achieved significant milestones, including the FDA approval of ZYCUBO® for Menkes disease and the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million. By developing products both internally and through a network of majority-owned and minority partner companies, Fortress aims to create a diversified, long-term revenue stream from commercial products, royalties, and equity stakes.
View full company profileTherapeutic Areas
Other Cutaneous Squamous Cell Carcinoma (cSCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| BCA101 | Bicara Therapeutics | Phase 1/2 |